A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

This Phase 1 study is testing a new investigational drug called SYNT-101 to assess how safe and tolerable it is at single and multiple dose levels in healthy adults and adults who are overweight. The study uses a randomized, double-blind, placebo-controlled design, meaning neither participants nor researchers know who receives the active drug versus placebo. Healthy and overweight adults aged 18 to 55 with no clinically significant health conditions, suitable veins for blood draws, and willingness to comply with all procedures are eligible, while those with known allergies to the drug, significant organ disease, or relevant health history are excluded. Participants will receive SYNT-101 or placebo in assigned doses and attend follow-up visits and a safety phone call over approximately the study duration. This summary was prepared to help patients understand the study in plain language.